StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)

Close on Nov 17, 2026Market cap $93.66MP/E –Yield –

Voyager Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Voyager Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$117.19M. For fiscal 2025 it was -$131.84M. The highest annual figure on record is $122.01M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$131.84M–
FY2024Dec 31, 2024-$83.29M-168.3%
FY2023Dec 31, 2023$122.01M–
FY2022Dec 31, 2022-$50.84M–
FY2021Dec 31, 2021-$73.62M-368.8%
FY2020Dec 31, 2020$27.38M–
FY2019Dec 31, 2019-$51.68M–
FY2018Dec 31, 2018-$91.10M–
FY2017Dec 31, 2017-$71.86M–
FY2016Dec 31, 2016-$41.30M–
FY2015Dec 31, 2015-$20.25M–
FY2014Dec 31, 2014-$14.37M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.39M–
Q1 FY2026Mar 31, 2026-$30.27M–
Q4 FY2025Dec 31, 2025-$29.93M–
Q3 FY2025Sep 30, 2025-$30.59M–
Q2 FY2025Jun 30, 2025-$36.63M–
Q1 FY2025Mar 31, 2025-$34.69M–
Q4 FY2024Dec 31, 2024-$38.30M-170.8%
Q3 FY2024Sep 30, 2024-$13.78M–
Q2 FY2024Jun 30, 2024-$15.03M–
Q1 FY2024Mar 31, 2024-$16.18M-113.2%
Q4 FY2023Dec 31, 2023$54.06M–
Q3 FY2023Sep 30, 2023-$29.51M-304.3%
Q2 FY2023Jun 30, 2023-$25.43M–
Q1 FY2023Mar 31, 2023$122.88M–
Q4 FY2022Dec 31, 2022-$24.56M-530.8%
Q3 FY2022Sep 30, 2022$14.44M–
Q2 FY2022Jun 30, 2022-$19.37M–
Q1 FY2022Mar 31, 2022-$21.35M–
Q4 FY2021Dec 31, 2021$5.70M–
Q3 FY2021Sep 30, 2021-$25.15M-129.7%
Q2 FY2021Jun 30, 2021-$28.59M–
Q1 FY2021Mar 31, 2021-$25.59M–
Q4 FY2020Dec 31, 2020-$23.73M–
Q3 FY2020Sep 30, 2020$84.53M–
Q2 FY2020Jun 30, 2020-$8.98M-197.7%
Q1 FY2020Mar 31, 2020-$24.43M–
Q4 FY2019Dec 31, 2019-$13.77M–
Q3 FY2019Sep 30, 2019-$17.81M–
Q2 FY2019Jun 30, 2019$9.19M–
Q1 FY2019Mar 31, 2019-$29.29M–
Q4 FY2018Dec 31, 2018-$23.16M–
Q3 FY2018Sep 30, 2018-$21.15M–
Q2 FY2018Jun 30, 2018-$25.69M–
Q1 FY2018Mar 31, 2018-$21.09M–
Q4 FY2017Dec 31, 2017-$12.35M–
Q3 FY2017Sep 30, 2017-$23.36M–
Q2 FY2017Jun 30, 2017-$18.64M–
Q1 FY2017Mar 31, 2017-$17.52M–
Q4 FY2016Dec 31, 2016-$13.84M–
Q3 FY2016Sep 30, 2016-$10.37M–

More Voyager Therapeutics figures

See a number that looks wrong?